Kexing Biopharm (688136) Key Financial Indicators

34.68
+0.04+0.12%

Market Closed Jan 16 15:00 CST

6.98BMarket Cap55.58P/E (TTM)

688136 Current Ratio

If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Kexing Biopharm shows that the company's current ratio is 1.50, indicating healthy liquidity.

Currency: CNY

Cumulative Quarterly

688136 Quick Ratio

Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Kexing Biopharm, the quick ratio is 1.38, indicating that the company can meet its short-term debt obligations.

Currency: CNY

Cumulative Quarterly

688136 Return on Equity (ROE)

Want to learn more about the financial health of Kexing Biopharm? The latest ROE figure is 6.64%, indicating that the company has stable profitability.

Currency: CNY

Cumulative Quarterly

688136 Return on Assets (ROA)

Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Kexing Biopharm, the total asset return on investment (ROA) is 3.32%.

Currency: CNY

Cumulative Quarterly

688136 Gross Margin

Gross margin can provide insight into a company's pricing strategy and cost structure. Check Kexing Biopharm's latest financial report to see how their gross margin is doing - currently at 63.54%.

Currency: CNY

Cumulative Quarterly

688136 Net Margin

For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Kexing Biopharm, the net profit margin is 9.51%, which is a good sign for its profitability.

Currency: CNY

Cumulative Quarterly

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"